Breakthrough: Bayer’s Gadoquatrane Shows Promising Results
Revolutionary Phase III Trial Results
Bayer has announced groundbreaking topline results from their Phase III QUANTI studies evaluating gadoquatrane, an innovative gadolinium-based contrast agent (GBCA) for magnetic resonance imaging (MRI). The revolutionary aspect of this…
